Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 18.21M shares rose 40.6% year over year, ahead of the +32.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 18.9% from the prior quarter. Over 3 fiscal years it compounded at +70.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.6% holds above the trailing-twelve-month pace of +32.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
18.21M+18.9% QoQ
Last fiscal yearDec 2025
15.31M+25.5% YoY
LTMMar 2026
16.57M+32.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.6%——
1 year+25.5%——
3-year CAGR+70.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
15.31M USD
Year-over-year change
+25.5%
4-year CAGR
+47.9%

Weighted Avg Shares vs competitors

How ELTX compares with its peers on the latest reported figures

  • ELTX's LTM Mar 2026 weighted avg shares of 16.57M shares is the 8th highest of the 9 companies compared; the peer median is 55.68M shares.
  • Its year-over-year change of +32.5% is the 4th highest of 9, against a peer median of +30.5%.
  • Over three fiscal years its annual growth of +70.3% compares with a peer median of +22.4%.
ELTX Competitors Peer median
Weighted Avg Shares for ELTX and competitors
Company Period LTM YoY 3-year CAGR
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding ELTX) 55.68M+30.5%+22.4%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.31M0000
Cost of Revenue1.23M1.06M1.17M1.18M1.13M
Gross Profit27.08M(1.06M)(1.17M)(1.18M)(1.13M)
Gross Margin95.6%————
Research & Development48.61M17.05M22.68M33.66M24.9M
Selling, General & Admin17.78M5.63M11.9M11.33M12.81M
Operating Expenses66.39M22.68M34.58M43.81M36.59M
Depreciation & Amortization801K1.06M1.17M1.18M1.13M
EBITDA(51.93M)(23.55M)(32.97M)(50.27M)(37.31M)
EBITDA Margin-183.4%————
Operating Income(39.31M)(23.73M)(35.75M)(44.99M)(37.71M)
Operating Margin-138.8%————
Interest Income3.39K64.83K373K777K776K
Interest Expense876.44K3.6M1.06M455K1.13M
Other Income / Expenses(15.27M)(4.48M)550K(6.91M)(1.86M)
Income Before Tax(54.57M)(28.21M)(35.2M)(51.9M)(39.57M)
Pre-Tax Margin-192.8%————
Income Tax Expense00000
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Net Margin-93.2%————
EPS (Basic)(19.32)(9.10)(6.96)(4.25)(2.58)
EPS (Diluted)(19.32)(9.10)(6.96)(4.25)(2.58)
Weighted Avg Shares3.2M3.1M5.06M12.2M15.31M
Weighted Avg Shares (Diluted)3.2M3.1M5.06M12.2M15.31M

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.